BIOCAD is one of the largest innovative biotechnology companies in Russia, which brings together world-class research centers, state-of-the-art pharmaceutical and biotechnological production, and preclinical and clinical studies that meet international standards.

BIOCAD is a full-cycle drug development company with activities ranging from molecular discovery to mass production and marketing support. The product portfolio currently consists of 61 products, including 9 original drugs; more than 40 products are at various stages of development. The drugs are intended for the treatment of cancer and autoimmune diseases.

BIOCAD employs over 2,600 people, of which about one-third are scientists and researchers.